+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Consideration of beta-1 adrenergic receptor polymorphisms along with traditional risk factors as predictors of prognosis in patients with heart failure



Consideration of beta-1 adrenergic receptor polymorphisms along with traditional risk factors as predictors of prognosis in patients with heart failure



Clinical Pharmacology & Therapeutics 75(2): P55



Traditional risk factors have been linked to heart failure (HF) severity. We investigated whether β1-adrenergic receptor (AR) genotypes and variable HF drug use offer additional prognostic information.Patients with documented HF were enrolled and followed for all-cause mortality, heart transplant, or HF hospitalization. Cox regression was used to examine the effects of covariates on outcome. Variables included traditional demographic, medical and social history, and laboratory parameters along with use of digoxin and spironolactone, β1AR codon 49 genotype, and β1AR codon 389 genotype. β-blocker, ACE inhibitor, and diuretic use were high at baseline and end of follow-up and not included in the model. Significance for inclusion in the model was set at 0.1.Patients (n=181) were followed for a median of 18 months (4 days min, 36 months max). Significant markers of HF prognosis are presented (Table). HF drugs with variable use (digoxin, spironolactone) and β1AR genotypes were not significant.Traditional risk factors associated with worse HF prognosis were verified in our population. β1AR genotypes and digoxin and spironolactone use were not associated with the composite endpoint. The guideline-driven high use of β-blockers in this population may have masked any β1AR genotype effects on endpoints.Clinical Pharmacology & Therapeutics (2004) 75, P55–P55; doi: 10.1016/j.clpt.2003.11.208Table 1. VariableHazard RatioP-valueSerum sodium0.88<0.0001NYHA class1.810.0002Creatinine1.040.004Male gender2.240.007Dyslipidemia history0.600.051Previous CABG1.660.054Diabetes history1.630.094

(PDF emailed within 0-6 h: $19.90)

Accession: 034640027

Download citation: RISBibTeXText

DOI: 10.1016/j.clpt.2003.11.208


Related references

Angiotensin system polymorphisms and traditional risk factors as predictors of heart failure prognosis. Clinical Pharmacology & Therapeutics 77(2): P63-P63, 2005

Impact of beta-2 Thr164Ile and combined beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients. Brazilian Journal of Medical and Biological Research 43(6): 565-571, 2011

Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. American Journal of Cardiology 102(6): 726-732, 2008

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and Genomics 15(3): 137-142, 2005

Relationship between beta-1 adrenergic receptor polymorphisms and the response to beta-blockers in patients with heart failure. Circulation 104(17 Suppl.): II 661-II 662, October 23, 2001

Interactions between beta1 and beta2 adrenergic receptor polymorphisms as risk factors for chronic heart failure. Revista Medica de Chile 136(11): 1371-1380, 2009

Polymorphisms of the beta-2 adrenergic receptor affect exercise capacity in patients with heart failure. Journal of Investigative Medicine 44(7): 394, 1996

Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circulation Research 86(8): 834-840, 2000

Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure. Bmc Cardiovascular Disorders 9: 50, 2010

Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovascular Drugs and Therapy 24(1): 49-60, 2010

Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. American Journal of Medicine 117(7): 451-458, 2004

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. British Journal of Clinical Pharmacology 71(4): 556-565, 2011

Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure. Journal of Cardiovascular Translational Research 2019, 2019

β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Molecular Medicine Reports 7(1): 259-265, 2014

β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis. Plos One 7(7): E37659, 2013